Glyscend taps CEO to lead oral obe­si­ty, type 2 di­a­betes can­di­date; Ex-Travec­ta chief bounces back af­ter com­pa­ny shut­down

As a new wave of type 2 di­a­betes and obe­si­ty drugs takes the in­dus­try by storm, Glyscend Ther­a­peu­tics has tapped a new CEO to lead the charge for its can­di­date de­signed to mim­ic meta­bol­ic surgery.

Sapan Shah is tak­ing the dri­ver’s seat at Glyscend as found­ing CEO Ashish Nim­gaonkar shifts to oth­er roles as chief med­ical of­fi­cer and head of R&D, the com­pa­ny an­nounced on Tues­day. The news comes just a few months af­ter Glyscend un­veiled topline da­ta from a Phase IIa sug­gest­ing its lead can­di­date, GLY-200, helped type 2 di­a­betes pa­tients achieve sig­nif­i­cant re­duc­tions in blood glu­cose and a de­crease in body weight. The com­pa­ny hopes the oral drug will have the same ef­fects as meta­bol­ic surgery with­out the cost and com­pli­ca­tions from the in­va­sive pro­ce­dure.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.